CRNX Crinetics Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRNX

Price (delayed)

$15.92

Market cap

$858.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.15

Enterprise value

$826.28M

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, ...

Highlights
The debt has declined by 39% since the previous quarter and by 34% year-on-year
CRNX's net income has dropped by 52% year-on-year and by 9% since the previous quarter
The quick ratio has decreased by 42% YoY and by 20% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.crinetics.com
Peers: OVID

Key stats

What are the main financial stats of CRNX
Market
Shares outstanding
53.91M
Market cap
$858.23M
Enterprise value
$826.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.71
Price to sales (P/S)
174.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
174.43
Earnings
Revenue
$4.74M
EBIT
-$163.92M
EBITDA
-$162.53M
Free cash flow
-$116.86M
Per share
EPS
-$3.15
Free cash flow per share
-$2.25
Book value per share
$5.88
Revenue per share
$0.09
TBVPS
$6.77
Balance sheet
Total assets
$352.18M
Total liabilities
$35.85M
Debt
$2.02M
Equity
$316.33M
Working capital
$317.46M
Liquidity
Debt to equity
0.01
Current ratio
12.45
Quick ratio
12.11
Net debt/EBITDA
0.2
Margins
EBITDA margin
-3,431.1%
Gross margin
100%
Net margin
-3,460.4%
Operating margin
-3,544.1%
Efficiency
Return on assets
-43.9%
Return on equity
-48.3%
Return on invested capital
-58.1%
Return on capital employed
-50.5%
Return on sales
-3,460.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRNX stock price

How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
-1.55%
1 week
-7.39%
1 month
-18.11%
1 year
-19.15%
YTD
-13.01%
QTD
-13.01%

Financial performance

How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$4.74M
Gross profit
$4.74M
Operating income
-$167.88M
Net income
-$163.92M
Gross margin
100%
Net margin
-3,460.4%
The net margin has surged by 65% year-on-year but it has declined by 18% since the previous quarter
The operating margin has soared by 65% YoY but it has contracted by 20% from the previous quarter
CRNX's operating income has plunged by 56% YoY and by 11% from the previous quarter
CRNX's net income has dropped by 52% year-on-year and by 9% since the previous quarter

Growth

What is Crinetics Pharmaceuticals's growth rate over time

Valuation

What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.71
P/S
174.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
174.43
The company's EPS fell by 13% YoY and by 5% QoQ
CRNX's P/B is 21% below its 5-year quarterly average of 3.5 and 8% below its last 4 quarters average of 3.0
CRNX's equity is down by 10% since the previous quarter and by 4.7% year-on-year
The P/S is 18% below the last 4 quarters average of 216.8
The revenue is down by 7% since the previous quarter

Efficiency

How efficient is Crinetics Pharmaceuticals business performance
The return on invested capital has surged by 66% year-on-year and by 6% since the previous quarter
The company's return on sales has surged by 65% YoY but it fell by 18% QoQ
The company's return on equity fell by 11% QoQ
The ROA has decreased by 9% from the previous quarter but it has increased by 4.1% YoY

Dividends

What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRNX.

Financial health

How did Crinetics Pharmaceuticals financials performed over time
The total liabilities has soared by 88% YoY and by 7% from the previous quarter
The current ratio has contracted by 42% YoY and by 19% from the previous quarter
The debt is 99% smaller than the equity
The debt has declined by 39% since the previous quarter and by 34% year-on-year
CRNX's equity is down by 10% since the previous quarter and by 4.7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.